ESC Congress 2026 Abstract
Semaglutide tied to survival in non-Hodgkin lymphoma on anthracyclines
In two matched groups of 994 adults, semaglutide was linked to hazard ratios of 0.20 for death and 0.47 for major heart events against unexposed patients.In two matched groups of 994 adults, semaglutide was linked to hazard ratios of 0.20 for death and 0.47 for major heart events against unexposed patients.
Cohort studySemaglutide
Who was studiedAdults with non-Hodgkin lymphoma receiving anthracyclines, median 584 days
What changedDeath was lower among semaglutide users than unexposed patients, with a hazard ratio of 0.20
The catchSemaglutide users had median follow-up of 584 days, limiting assessment of longer-term survival